Adicet Bio

ACET Rare disease Lead: Phase 1 3 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-12

Catalyst timeline

Prula-cel Ph1 interim3Q 2026Prula-cel Ph1 interim, 3Q 2026, major
Prula-cel interim2H 2026Prula-cel interim, 2H 2026, material
Prula-cel RA Ph1 interim2H 2026Prula-cel RA Ph1 interim, 2H 2026, material
ADI-212 IND filing3Q 2026ADI-212 IND filing, 3Q 2026, notable
Prula-cel / pivotal program start2H 2026Prula-cel / pivotal program start, 2H 2026, notable
in vivo CAR-T platform readout2H 2026in vivo CAR-T platform readout, 2H 2026, notable
Prula-cel filingSep 2026Prula-cel filing, Sep 2026, material
ADI-212 trial start4Q 2026ADI-212 trial start, 4Q 2026, routine
In vivo CAR-T pipeline corporate2H 2027In vivo CAR-T pipeline corporate, 2H 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (8 active programs)

prula-cel

prulacabtagene leucel · ADI-001

Cell Target: CD20

ADI-212

Cell Target: PSMA

Metastatic Castration-Resistant Prostate Cancer Preclinical CRISPR Therapeutics NCT07793435

Technology platforms

In Vivo CAR-T

Differentiated in vivo CAR-T platform designed to optimize in vivo T cell transduction to yield highly cytolytic CAR-T therapy; preclinical programs targeting multiple myeloma, non-Hodgkin's lymphoma, and solid tumor indications

Targets: BCMA, CD19

Discontinued (1)

ADI-270 — Clear Cell Renal Cell Carcinoma · strategic reprioritization of pipeline to optimize development of assets

Biotech Distilled coverage (3)

2026-09-02 UPDATE: Adicet Bio (ACET) - The Clock Is Set 🔒 Paid
2026-08-27 UPDATE: Adicet Bio (ACET) - The Second Asset Clears 🔒 Paid
2026-08-07 Adicet Bio (ACET) — Scientific Deep Dive for Prula-cel, ADI-212 and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.